UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma

PloS one, 2016-03, Vol.11 (3), p.e0150836-e0150836

2016

Volltextzugriff (PDF)

Synthesis and Cancer Stem Cell-Based Activity of Substituted 5‑Morpholino‑7H‑thieno[3,2‑b]pyran-7-ones Designed as Next Generation PI3K Inhibitors

Journal of medicinal chemistry, 2013-03, Vol.56 (5), p.1922-1939

2013

Volltextzugriff (PDF)

Dual-activity PI3K–BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis

Proceedings of the National Academy of Sciences - PNAS, 2017-02, Vol.114 (7), p.E1072-E1080

2017

Volltextzugriff (PDF)

SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer

Molecular cancer therapeutics, 2019-06, Vol.18 (6), p.1036-1044

2019

Volltextzugriff (PDF)

Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma

Molecular cancer therapeutics, 2016-11, Vol.15 (11), p.2553-2562

2016

Volltextzugriff (PDF)

Macrophage Syk-PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression

Molecular cancer therapeutics, 2020-03, Vol.19 (3), p.755-764

2020

Volltextzugriff (PDF)

A Vascular Targeted Pan Phosphoinositide 3-Kinase Inhibitor Prodrug, SF1126, with Antitumor and Antiangiogenic Activity

Cancer research (Chicago, Ill.), 2008, Vol.68 (1), p.206-215

2008

Volltextzugriff (PDF)

Association of high microvessel αvβ3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126

Oncotarget, 2017-08, Vol.8 (32), p.52193-52210

2017

Volltextzugriff (PDF)

An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo

Cancer chemotherapy and pharmacology, 2013-04, Vol.71 (4), p.867-881

2013

Volltextzugriff (PDF)

Abstract 109: Myeloid Syk-PI3Kg-HIF axis inhibits anti-tumor adaptive immunity: In silico design of a “first in class” novel dual-Syk/PI3K inhibitor, SRX3207, to block the immunosuppressive tumor microenvironment

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.109-109

2019

Volltextzugriff (PDF)

Abstract LB-211: A novel dual epigenetic/kinase inhibitory platform: SF2523 and analogues as first-in-class PI3K/BRD4 inhibitors

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.LB-211-LB-211

2016

Volltextzugriff (PDF)

Abstract LB-298: The novel triple PI3K-CDK4/6-BRD4 inhibitor SRX3177 harnesses synthetic lethality relationships to orthogonally disrupt cancer cell signaling

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.LB-298-LB-298

2017

Volltextzugriff (PDF)

Abstract A27: Dual PI3K/BRD4 (kinase/epigenetic) inhibitors for maximal MYC control in cancer therapeutics

Molecular cancer therapeutics, 2015-07, Vol.14 (7_Supplement), p.A27-A27

2015

Volltextzugriff (PDF)

Macrophage Syk-PI3Kγ inhibits anti-tumor immunity: SRX3207, a novel dual Syk-PI3K inhibitory chemotype relieves tumor immunosuppression

Molecular cancer therapeutics, 2020-01, Vol.19 (3), p.755-764

2020

Volltextzugriff (PDF)

Reagents for the stepwise functionalization of spermidine, homospermidine, and bis(3-aminopropyl)amine

Journal of organic chemistry, 1984-08, Vol.49 (16), p.2997-3001

1984

Volltextzugriff (PDF)

Synthesis and Cancer Stem Cell-Based Activity of Substituted 5-Morpholino-7 H -thieno[3,2- b ]pyran-7-ones Designed as Next Generation PI3K Inhibitors

Journal of medicinal chemistry, 2013-03, Vol.56 (5), p.1922-1939

2013

Volltextzugriff (PDF)

SF1126, a Pan-PI3K Inhibitor Has Superior Preclinical Activity to CAL-101 a PI3K Delta-Specific Inhibitor in Aggressive B-Cell Non-Hodgkin's Lymphoma

Blood, 2011-11, Vol.118 (21), p.2720-2720

2011

Volltextzugriff (PDF)

Phase I Study of Novel Prodrug Dual PI3K/mTOR Inhibitor SF1126 In B-Cell Malignancies

Blood, 2010-11, Vol.116 (21), p.1783-1783

2010

Volltextzugriff (PDF)

SF1126, a Novel PI3K Inhibitor Results in Downstream Inhibition of the PI3K Axis and Displays Sequence Specific Synergy When Combined with Bortezomib in Multiple Myeloma Cells

Blood, 2008-11, Vol.112 (11), p.5167-5167

2008

Volltextzugriff (PDF)

Association of high microvessel α v β 3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126

Oncotarget, 2017-08, Vol.8 (32), p.52193

2017

Volltextzugriff (PDF)

PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma: e0150836

PloS one, 2016-03, Vol.11 (3)

2016

Volltextzugriff (PDF)

Preliminary Results of a Phase I Study of the Pan-PI3 Kinase Inhibitor SF1126 in Patients with Relapsed and Refractory Myeloma

Blood, 2009-11, Vol.114 (22), p.3879-3879

2009

Volltextzugriff (PDF)

SF1126, a Pan-PI3K Inhibitor has Potent Pre-Clinical Activity in Aggressive B-Cell Non-Hodgkin Lymphomas by Inducing Cell Cycle Arrest and Apoptosis

Journal of cancer science & therapy, 2012, Vol.4 (7)

2012

Volltextzugriff (PDF)

Pharmacokinetics, Dosimetry and Toxicity of Holmium-166-DOTMP for Bone Marrow Ablation in Multiple Myeloma

The Journal of nuclear medicine (1978), 1995-05, Vol.36 (5), p.730

1995

Volltextzugriff (PDF)

Amines and Polyamines from Nitriles

Synthesis (Stuttgart), 1984, Vol.1984 (9), p.782-784

1984

Volltextzugriff (PDF)

1 – 25 von 29

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(29)

Sprache

Englisch
(29)

Erscheinungsjahr

n.n

Thema

Science & Technology
(14)
Life Sciences & Biomedicine
(10)
Humans
(8)
Animals
(7)
Mice
(6)
Oncology
(5)
Phosphatidylinositol 3-Kinases - Antagonists & Inhibitors
(5)
Xenograft Model Antitumor Assays
(5)
Antineoplastic Agents - Pharmacology
(4)
Cell Line, Tumor
(4)
Apoptosis
(3)
Biological And Medical Sciences
(3)
Cell Proliferation - Drug Effects
(3)
Morpholines - Pharmacology
(3)
Physical Sciences
(3)
Aliphatic Compounds
(2)
Antineoplastic Agents
(2)
Brd4
(2)
Cancer
(2)
Cancer Research
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma

Synthesis and Cancer Stem Cell-Based Activity of Substituted 5‑Morpholino‑7H‑thieno[3,2‑b]pyran-7-ones Designed as Next Generation PI3K Inhibitors

Dual-activity PI3K–BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis

SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer

Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma

Macrophage Syk-PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression

A Vascular Targeted Pan Phosphoinositide 3-Kinase Inhibitor Prodrug, SF1126, with Antitumor and Antiangiogenic Activity

Association of high microvessel αvβ3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126

An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo

Abstract 109: Myeloid Syk-PI3Kg-HIF axis inhibits anti-tumor adaptive immunity: In silico design of a “first in class” novel dual-Syk/PI3K inhibitor, SRX3207, to block the immunosuppressive tumor microenvironment

Abstract LB-211: A novel dual epigenetic/kinase inhibitory platform: SF2523 and analogues as first-in-class PI3K/BRD4 inhibitors

Abstract LB-298: The novel triple PI3K-CDK4/6-BRD4 inhibitor SRX3177 harnesses synthetic lethality relationships to orthogonally disrupt cancer cell signaling

Abstract A27: Dual PI3K/BRD4 (kinase/epigenetic) inhibitors for maximal MYC control in cancer therapeutics

Macrophage Syk-PI3Kγ inhibits anti-tumor immunity: SRX3207, a novel dual Syk-PI3K inhibitory chemotype relieves tumor immunosuppression

Reagents for the stepwise functionalization of spermidine, homospermidine, and bis(3-aminopropyl)amine

Synthesis and Cancer Stem Cell-Based Activity of Substituted 5-Morpholino-7 H -thieno[3,2- b ]pyran-7-ones Designed as Next Generation PI3K Inhibitors

SF1126, a Pan-PI3K Inhibitor Has Superior Preclinical Activity to CAL-101 a PI3K Delta-Specific Inhibitor in Aggressive B-Cell Non-Hodgkin's Lymphoma

Phase I Study of Novel Prodrug Dual PI3K/mTOR Inhibitor SF1126 In B-Cell Malignancies

SF1126, a Novel PI3K Inhibitor Results in Downstream Inhibition of the PI3K Axis and Displays Sequence Specific Synergy When Combined with Bortezomib in Multiple Myeloma Cells

Association of high microvessel α v β 3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126

PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma: e0150836

Preliminary Results of a Phase I Study of the Pan-PI3 Kinase Inhibitor SF1126 in Patients with Relapsed and Refractory Myeloma

SF1126, a Pan-PI3K Inhibitor has Potent Pre-Clinical Activity in Aggressive B-Cell Non-Hodgkin Lymphomas by Inducing Cell Cycle Arrest and Apoptosis

Pharmacokinetics, Dosimetry and Toxicity of Holmium-166-DOTMP for Bone Marrow Ablation in Multiple Myeloma

Amines and Polyamines from Nitriles

Suchergebnisse filtern